<DOC>
	<DOCNO>NCT00899795</DOCNO>
	<brief_summary>RATIONALE : Studying sample bone marrow patient cancer healthy volunteer laboratory may help doctor learn change occur bone marrow stromal ( connective tissue ) cell . It may also help doctor understand effect alkylating agent bone marrow stromal cell . PURPOSE : This laboratory study evaluate stromal cell patient acute myeloid leukemia , myelodysplastic syndrome , Fanconi anemia ; patient expose alkylating agent ; healthy volunteer .</brief_summary>
	<brief_title>Evaluating Cell Damage Patients With Acute Myeloid Leukemia , Myelodysplastic Syndromes , Fanconi Anemia ; Patients Who Were Exposed Alkylating Agents ; Healthy Volunteers</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine abnormal stromal function patient acute myeloid leukemia ( AML ) , myelodysplastic syndrome ( MDS ) , Fanconi anemia ; patient expose alkylating agent ; healthy volunteer . Secondary - Determine whether clonal progenitor patient secondary AML MDS resistant select extracellular apoptotic cue . - Determine whether stromal function patient secondary AML MDS aberrant stromal function patient primary AML MDS . - Determine whether cytotoxic agent know induce secondary MDS AML influence supportive function bone marrow stroma . - Determine whether cytoprotective agent reduce cytotoxicity genotoxicity hematopoietic progenitor cell stromal cell . OUTLINE : Patients healthy volunteer undergo bone marrow sample collection . Progenitor cell grown culture . Cell survival quantify flow cytometric cytogenetic analysis , sister chromatid exchange , FISH chromosome 11 change ( etoposide-exposed sample ) . PROJECTED ACCRUAL : A total 24 patient healthy volunteer accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : Diagnosis acute myeloid leukemia myelodysplastic syndrome require bone marrow aspiration/biopsy clinical purpose Primary secondary disease Diagnosis Fanconi anemia positive mitomycin C test ( age 5 55 year ) Received prior chemotherapy contain follow alkylating agent : mechlorethamine , chlorambucil , cyclophosphamide , melphalan , busulfan , topoisomerase inhibitor Healthy volunteer ( age 18 ) , meet follow criterion : CBC normal WBC &gt; 1,000/mm³ Hemoglobin &gt; 10 g/dL Platelet count &gt; 70,000/mm³ No bone marrow metastases No evidence nonhematopoietic malignancy PATIENT CHARACTERISTICS : ECOG performance status 02 No clinical sign symptom acute subacute infection ( viral , bacterial , fungal infection ) No allergy lidocaine xylocaine PRIOR CONCURRENT THERAPY : See Disease Characteristics More 6 month since prior cytotoxic immunosuppressive agent No prior extensive pelvic radiotherapy ( &gt; 20 Gy )</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>